维普期刊资源整合服务平台（V6.5）

61篇 您的检索式：作者名="MUGGIA F"

选中清除导出查看参考文献查看引证文献引用追踪共4页首页上一页第1页下一页末页 /4 跳转

	题名	作者	年代	出处	被引量
1	Concurrent radiotherapy, paclitaxel and dose escalating carboplatin in the treatment of cervical cancer-a phase Ⅰ study显示文摘	Addeo D Blank S Muggia F	2008	Anlicancer Res2008，28，5：	1
2	A phase Ⅱstudy of liposomal lurtotecan (OSI-211)in patients with topotecan resistant ovarian cancer 显示文摘	Seiden MV Muggia F Astrow A	2004	Glynecol Oncol2004，93，1：	1
3	BRCA genes:lessons learned from experimental and clinical cancer显示文摘	Muggia F Safra T Dubean L		0，，1：	1
4	Paelitaxel-Induced Apoptosis and Mitotic Arrest Assessed by Serial Fine-Needle Aspiration : Implications for Early Prediction of Breast Cancer Response to Neoadjuvant Treatment 显示文摘	SYMMANS W F VOLM M D SHAPIRO R L PERKINS A B KIM A Y DEMARIA S YEE H T MCMULLEN H ORATZ R KLEIN P FORMENTI S C MUGGIA F	2000	Clin Cancer Res2000，6，12：	1
5	Complement activation by Ctemophor EL as a possible contributor to hypersensitivity to Paclilaxel:an in vitro study显示文摘	SZEBENI J MUGGIA F M AI VING C R	1998	J Natl Cancer Inst1998，90，4：	1
6	Phase Ⅱ study of liposomal doxorubicin in refractory ovarian cancer: antitu- mor activity and toxicity modification by liposomal encapsulation 显示文摘	MUGGIA F M HAINSWORTH J D JEFFERS S	1997	J Clin Oncol1997，15，3：	1
7	Epidermal growth factor receptor inhibitors for the treatment of epithelial ovarian cancer显示文摘	Blank SV Chang R Muggia F	2005	Oncology2005，19，4：	1
8	A phase Ⅱ study of liposomal lurtotecan(OSI-211)in patients with topotecan resistant ovarian cancer显示文摘	Seiden MV Muggia F Astrow A	2004	Glynecol Oncol2004，93，1：	1
9	Low doses of dexamethasone protect against paclitaxel(Taxol)-related hypersensitivity reactions following cycle 1显示文摘	Uziely B Jeffers S Muggia F	1994	Ann Oncol1994，5，：	1
10	Breast cancer arising in a BRCA-mutated background: therapeutic implications from an animal model and drug development显示文摘	Fasano J Muggia F	2009	Ann Oncol2009，20，60：	1
11	The cancer therapy evaluation progranm of the natinal institute显示文摘	Muggia F M	1981	Semi Oncol1981，8，：	1
12	Platinum compounds 30 years after the introduction of cisplatin: implications for the treatment of ovarian cancer显示文摘	MUGGIA F	2009	Gy- necol Oncol2009，112，1：	1
13	Targeting HER2 in ovarian and uterine cancers: challenges and future directions显示文摘	Teplinsky E Muggia F	2014	Gy- necol Oncol2014，135，2：	1
14	Pegylated Liposomal Doxorubicin (Doxil) :Reduced Clinical Cardiotoxicity in Patients Reaching or Exceeding Cumulative Doses of 500mg/m^2 显示文摘	Safra T Muggia F Jeffers S	2000	Ann Oncol2000，11，：	1
15	Concurrent radio- therapy, paclitaxel and dose escalating carboplatin in the treatment of cervical cancer-a phase I study 显示文摘	Addeo D Blank S Muggia F	2008	Antican- cer Res2008，28，5：	1
16	Targeting HER2 in ovarian and u- terine cancers : challenges and future directions 显示文摘	Teplinsky E Muggia F	2014	Gyne- col Oncol2014，135，2：	1
17	Preclinical pharmacokinetics and stability of isophosphoramide 显示文摘	Zheng J J Chan KK Muggia F	1994	Cancer Chemother Pharmacol1994，33，：	1
18	Phase Ⅰ/Ⅱ clinical and pharmacokinetic evaluation of liposomal daunorubicin显示文摘	Cill PS Espina BM Muggia F	1995	J Clin Oncol1995，13，4：	1
19	Camptothecins:a review of their development and schedules of administration显示文摘	OLeary J Muggia F M		0，，：	1
20	Breast cancer arising in a BRCA - mutated background: therapeutic implications from an animal model and drug development显示文摘	Fasano J Muggia F	2009	Annals of Oncology2009，20，4：	1

返回顶部每页显示：

共4页首页上一页第1页下一页末页 /4 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示